Istiratumab

N/A

Report date: 2023/08/01 20:00:44

Base Information

Drug NameIstiratumab

Drug Alias NameMM-141XLR461MD3M (UNII code)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonistsInsulin-like growth factor I receptor antagonists

TargetsInsulin-like growth factor I receptorReceptor tyrosine-protein kinase erbB-3

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungPancreatic NeoplasmsColorectal Neoplasms +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesPoland +[7]

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesShire Development Llc Adimab LLC Merrimack Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMerrimack Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsCarcinoma, Non-Small-Cell LungPancreatic NeoplasmsColorectal Neoplasms +[5]

Other Information

ATC CodeN/A